Related Experiment Video
Updated: Aug 23, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
[Human papillomavirus and cervical cancer: presence and future of vaccination]
1Abteilung für Gynäkologie und gynäkologische Onkologie, Universitätsklinik für Frauenheilkunde, Wien, Osterreich. elmar.joura@meuniwien.ac.at
Abstract:
The very close relation between human papillomavirus (HPV) and cervical cancer is evident. A vaccine has been awaited for a longtime. After excellent results of phase II trials, a large worldwide phase III trial on a vaccine against HPV of high (types 16, 18) and low malignant potential (types 6, 11) is ongoing. If the vaccine is effective, registered and launched, at least three decades will pass until the incidence of invasive cervical cancer will drop significantly. The prevalence of premalignant lesions and genital warts may be reduced earlier. As, due to the high number of different oncogenic HPV types, complete prevention can hardly be achieved, screening will be necessary in the future. The screening intervals have to be redefined since the risk will decrease.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Poliomyelitis
Smallpox
Infectious Diseases and Their Occurrence
Cancer Prevention
Some...